In February, the United States came within weeks of running out of preservative-free methotrexate, a generic drug that is an essential component of chemotherapy treatments for the most common childhood cancer, acute lymphoblastic ...
Apr 24, 2012
0
0
One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when ...
Oct 26, 2011
0
0
A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological ...
Nov 17, 2021
0
1
A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human ...
Jan 17, 2020
1
5
(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Oct 26, 2012
0
0
(Medical Xpress)—University of Rochester Medical Center scientists believe they are the first to identify genes that underlie the growth of primitive leukemia stem cell, and then to use the new genetic signature to identify ...
Aug 27, 2012
0
0
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
Nov 28, 2012
0
0
When preliminary tests show that a new drug has remarkable effectiveness against a lethal illness, everyone wants to know how it works. Often, a mechanism of action is hard to pin down, but when it can be, a candidate drug's ...
Nov 30, 2015
0
55
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Sep 4, 2012
0
0
Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely ...
Sep 3, 2015
0
132
